GlassScriptPhysician profile
Michael B Carter
NPI 1174960025
$767.32
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $479 · 2023: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $288.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $125.06 | 2022-2023 | Ubrelvy |
| Novo Nordisk INC | $115.87 | 2022-2023 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $92.81 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $64.79 | 2022-2023 | Rexulti |
| Gilead Sciences, INC. | $48.76 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.49 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.59 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.79 | 2023 | |
| Lilly USA, LLC | $36.48 | 2022-2023 | Mounjaro, Trulicity |
| Merck Sharp & Dohme LLC | $35.66 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $29.70 | 2022 | |
| Amgen INC. | $24.74 | 2023 | Otezla, Repatha |
| Exact Sciences Corporation | $22.77 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $19.61 | 2023 | Trelegy Ellipta |
| Lundbeck LLC | $14.34 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $13.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.